One in seven Americans suffers from fecal incontinence, but is anyone talking about it? Augusta University expert offers treatments, research to help

Mar 7, 2022

5 min

Satish Rao, MD

Bowel or fecal incontinence, according to the Mayo Clinic, “is the inability to control bowel movements, causing stool (feces) to leak unexpectedly from the rectum. Also called bowel incontinence, fecal incontinence ranges from an occasional leakage of stool while passing gas to a complete loss of bowel control. Common causes of fecal incontinence include diarrhea, constipation, and muscle or nerve damage. The muscle or nerve damage may be associated with aging or with giving birth.”




Dr. Satish Rao is a seasoned gastroenterologist and an expert in digestive health, particularly the brain-gut connection. Rao, a professor of medicine at the Medical College of Georgia at Augusta University, recently offered a Q&A on the topic of fecal incontinence with the journal Gastroenterology & Hepatology.



What is the prevalence of fecal incontinence in the adult population?


Surveys have indicated a prevalence of approximately 9% to 10% in the United States. A recent study reported a 14% prevalence, although this study was Internet-based and, thus, may not have included many elderly patients, as they may not be as computer-savvy as younger patients.

It is safe to say that one in seven Americans currently suffers from fecal incontinence. Prevalence appears to be equal in men and women, although women outnumber men almost three to one when it comes to gastroenterology clinic visits and health care-seeking. Men may be too embarrassed to bring the issue of fecal incontinence to the attention of a physician, but when asked about it, they will admit and discuss it.

Also, extracting information from a patient about fecal incontinence depends on how the question is asked. Asking patients whether they have daily leakage vs whether they ever have had leakage or have had leakage in the past month will elicit different responses that a clinician may interpret differently. It is important to remember that leakage is not a physiologic event that a healthy adult should have at any time, even once a month or once a year. Not having the capacity to control bowel evacuation or having leakage unaware of its occurrence signals an abnormality.


What are notable risk factors for fecal incontinence?


In women, pregnancy can be a risk factor, particularly if giving birth involves pelvic tissue damage, such as injury inflicted by forceps use or the unfortunate occurrence of a significant tear. Neurologic or back injuries are other common risk factors. Also, chronic diarrhea can progress to fecal incontinence owing to severe irritation of the rectum or irritants in stool. Further, any condition that changes the ability of rectal capacity can result in fecal incontinence. These circumstances can include surgery or radiation to the rectal area.


Hear from a patient and learn more about Rao's research using magnetic stimulation to treat fecal incontinence.



What treatment modalities are currently available?


Simple, conservative treatment consists of educating patients about fecal incontinence and instructing them to avoid precipitating events. For example, although many people love to have a meal followed by a cup of coffee and a walk, such a sequence of activities is ill-advised for an incontinent patient: the meal provokes a gastric-colonic response, coffee is a powerful colonic stimulant, and exercise also stimulates motility. This triad creates the perfect storm for a stool leakage or accident while the patient is out on the after-dinner walk.

Antidiarrheal therapies can be very effective but only in approximately 15% to 20% of patients. Another treatment is biofeedback, which can correct muscle weakness using behavioral techniques. Biofeedback provides resolution in approximately 50% to 70% of patients.

The traditional model of office-based biofeedback requires that the patient make 6 or even up to 10 visits to a specialty clinic. This may mean that some patients must drive very long distances to an appropriate care facility that is staffed with trained personnel or physical therapists. This scenario presents a significant challenge for many patients, which is increasingly being recognized by health care professionals and researchers.

Good devices for home-based biofeedback have been scarce; however, such a device was recently approved by the US Food and Drug Administration. The research center at Augusta University has tested it in a clinical trial setting and found it to be quite effective as a home biofeedback treatment.

Dextranomer is another treatment modality. It involves injection of small beads of dextran polymers into the anorectal region. The beads form a protective cuff or a buffer to stop stool leakage.

Another treatment modality is sacral nerve stimulation using the Medtronic InterStim system. The patient is outfitted with a pacemaker-like device with wires that continuously stimulate the sacral nerves that control stool events.

In the case of a torn muscle, suturing the torn ends to reduce the size of the anorectal opening is usually useful for women postpartum, although the effect may not be sustained in the long term.



What emerging treatments and research should clinicians be aware of?


One emerging treatment developed at Augusta University’s Clinical Research Center is called translumbosacral neuromodulation therapy (TNT). TNT is similar to TAMS and involves the fecal delivery of magnetic energy through an insulated coil to the lumbosacral nerves that regulate anorectal function. The pulses generated are of the same strength as those of magnetic resonance imaging. The team at Augusta University’s research center has shown that TNT mechanistically improves nerve function and substantively improves stool leakage. A sham-controlled study and long-term study are currently underway at Augusta University and Harvard University’s Massachusetts General Hospital. These studies are being sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases.

A multicenter study sponsored by the National Institutes of Health that the team at Augusta University also is involved with is the FIT (Fecal Incontinence Treatment) trial. This randomized study compares biofeedback with dextranomer injection.

Also, as mentioned, tools are becoming available for home biofeedback that should allow many more affected patients to receive treatment because they can do so in the comfort of their own home. The research center at Augusta University is working on a novel home biofeedback protocol for the treatment of constipation and fecal incontinence.

Thus, novel noninvasive tools are emerging for fecal incontinence. The repertoire of current and emerging tools holds the promise of improved outcomes for patients with fecal incontinence.


Rao is also the founder of the Augusta University Digestive Health Center. He is available to speak to media regarding any aspect of digestive health -- simply click on his icon now to arrange an interview today.

Connect with:
Satish Rao, MD

Satish Rao, MD

Digestive Health Expert

Dr. Satish Rao, a seasoned gastroenterologist, is an expert in digestive health, particularly the brain-gut connection.

Bowel movementsConstipationMotilityFructose intoleranceBrain-gut connection
Powered by

You might also like...

Check out some other posts from Augusta University

Augusta University's Simon Medcalfe on the Real Economics of Hosting the World Cup featured image

1 min

Augusta University's Simon Medcalfe on the Real Economics of Hosting the World Cup

With the World Cup underway across the U.S., Canada, and Mexico, Dr. Simon Medcalfe, economist at Augusta University's Hull College of Business, wrote for Augusta Business Daily about why FIFA's headline economic projections for the tournament don't hold up. His piece breaks down why most of the spending tied to hosting the event isn't new activity but rather it's money that would have been spent elsewhere regardless. As Medcalfe put it: "New spending is not created; it is just moved around." Read his full column in Augusta Business Daily :  Dr. Medcalfe is a Professor of Economics and Finance at Augusta University, with research spanning sports economics, community and economic development, and social determinants of health. He holds a PhD in Business/Managerial Economics from Lehigh University. If you're covering the economics of hosting major sporting events, public subsidies for host cities, or the gap between projected and actual tourism impact, Dr. Medcalfe is available for comment. Click on the contact button in his profile below. 

Can a Mother's ZIP Code Shape a Baby's Future? featured image

2 min

Can a Mother's ZIP Code Shape a Baby's Future?

Where an expectant mother lives might reveal important clues about her baby's health before birth. According to a recent Augusta University Jagwire article, researchers at the Medical College of Georgia have found that mapping birth outcomes by ZIP code can help identify communities where mothers and newborns face greater health risks, providing valuable information for healthcare providers and public health officials. The two-part study out of the Department of Anesthesiology and Perioperative Medicine at the Medical College of Georgia at Augusta University, led by Mary Arthur, MD, explored the relationship between neighborhood characteristics and neonatal outcomes. By combining geographic mapping with maternal and infant health data, the researchers identified areas with higher rates of adverse birth outcomes and examined how factors such as access to prenatal care and other social determinants of health might contribute to those disparities. The findings suggest that geographic data can become a valuable tool for improving maternal and infant health. By identifying communities at greater risk, healthcare systems and policymakers can better target prenatal education, outreach programs and healthcare resources to support expectant mothers before complications arise. For journalists covering maternal health, healthcare disparities and public policy, Arthur offers valuable insight into how community-level data can help guide interventions that improve pregnancy outcomes and give more babies a healthier start in life. "The maps make it very easy to visualize those ZIP codes that link to poor neonatal outcomes. They're also helpful for planning strategic interventions to help the people who live in those particular areas in terms of making sure there are outreach programs for mothers in those areas to have access to prenatal care." Mary Arthur, MD To learn more about this important research and connect with Mary Arthur, contact AU's External Communications Team mediarelations@augusta.edu to arrange an interview today.

Can One Gene Change the Future of Heart Disease? featured image

2 min

Can One Gene Change the Future of Heart Disease?

Heart disease remains the world's leading cause of death, but researchers are continuing to uncover the genetic mechanisms that drive it. According to a recent Augusta University Jagwire article highlighting new research, scientists are investigating how a little-studied gene might influence the development of cardiovascular disease and whether it could become a future target for treatment. At the center of the research is Kunzhe Dong, PhD, an investigator at Augusta University's Immunology Center of Georgia, who is examining the role of the SH3BGRL2 gene in cardiovascular cells. While the gene has previously been associated with cancer biology, early findings suggest it might also play an important role in regulating how blood vessels respond to stress and injury. Understanding that relationship could reveal new biological pathways involved in heart disease and identify novel opportunities for precision medicine. The research aims to determine how changes in gene expression affect the function of cardiovascular cells and contribute to disease progression. By better understanding these molecular mechanisms, scientists hope to identify new therapeutic targets and improve the ability to prevent or treat cardiovascular disease before irreversible damage occurs. The work also reflects a broader shift toward precision medicine, where treatments are tailored to the underlying biology of each patient rather than relying solely on traditional risk factors. "This gene is well known in one field, but now we're seeing it's also important in cardiovascular cells." Kunzhe Dong, PhD To learn more about this research and connect with Kunzhe Dong, contact AU's External Communications Team mediarelations@augusta.edu to arrange an interview today.

View all posts